The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

The Large Molecule Bioanalytical Technologies Market is expected to grow from USD 9.29 Billion in 2024 to USD 16.76 Billion ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response.

The lyophilized injectable market is poised for growth due to increasing demand for biologics and specialty drugs, R&D activities, and global collabo ...

The Global Single-use Bioreactors Market is set to witness a healthy growth rate of 20% by 2029. Technological innovations ...

FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by th ...

We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a ...